GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Common Stock

LSB (LakeShore Biopharma Co) Common Stock : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Common Stock?

LakeShore Biopharma Co's quarterly common stock increased from Sep. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) but then stayed the same from Mar. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

LakeShore Biopharma Co's annual common stock increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) and increased from Mar. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).


LakeShore Biopharma Co Common Stock Historical Data

The historical data trend for LakeShore Biopharma Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Common Stock Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Common Stock
- - - -

LakeShore Biopharma Co Quarterly Data
Mar21 Sep21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LakeShore Biopharma Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


LakeShore Biopharma Co Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.